MindBio Therapeutics Corp.
MBIO
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.66% | -4.71% | -57.70% | -94.82% | 0.29% |
| Depreciation & Amortization | -- | 83.49% | -- | -21.41% | 63.58% |
| Other Operating Expenses | -- | -- | -44.20% | -- | -- |
| Total Operating Expenses | -61.93% | 20.07% | -53.43% | -97.89% | 6.88% |
| Operating Income | -152.16% | -910.84% | 53.43% | 75.02% | 178.00% |
| Income Before Tax | -1,271.68% | -857.85% | 75.41% | 92.33% | 124.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,271.68% | -857.85% | 75.41% | 92.33% | 124.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -300.00% | -- | -- |
| Net Income | -1,269.90% | -847.13% | 75.04% | 92.33% | 124.57% |
| EBIT | -152.16% | -910.84% | 53.43% | 75.02% | 178.00% |
| EBITDA | -142.77% | -319.75% | -- | -- | 206.31% |
| EPS Basic | -1,200.00% | -500.00% | 81.82% | 80.00% | 105.71% |
| Normalized Basic EPS | -350.00% | -450.00% | 85.71% | 77.78% | 104.55% |
| EPS Diluted | -1,200.00% | -500.00% | 81.82% | 80.00% | 105.71% |
| Normalized Diluted EPS | -350.00% | -450.00% | 85.71% | 77.78% | 104.55% |
| Average Basic Shares Outstanding | 2.14% | 34.90% | 21.66% | -61.06% | 347.92% |
| Average Diluted Shares Outstanding | 2.14% | 34.90% | 21.66% | -61.06% | 347.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |